Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.

@article{Guidetti2014PhaseIS,
  title={Phase II study of perifosine and sorafenib dual-targeted therapy in patients with relapsed or refractory lymphoproliferative diseases.},
  author={Anna Guidetti and Carmelo Carlo-Stella and Silvia Laura Locatelli and Walter Malorni and Roberta Mortarini and Simonetta Viviani and Domenico Russo and Alfonso Marchiano and Roberto Sorasio and Anna Dodero and Lucia Farina and L. Giordano and Massimo Di Nicola and Andrea Anichini and P. Poggi – Corradini and Alessandro Massimo Gianni},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2014},
  volume={20 22},
  pages={5641-51}
}
PURPOSE To evaluate safety and activity of perifosine and sorafenib combination therapy in patients with lymphoproliferative diseases. EXPERIMENTAL DESIGN Patients with relapsed and refractory lymphoproliferative diseases received perifosine (50 mg twice daily) for 1 month. Patients achieving less than partial response (PR) after perifosine alone were administered the combination therapy [perifosine plus sorafenib (400 mg twice daily)] until progressive disease (PD) or unacceptable toxicity… CONTINUE READING
9 Extracted Citations
51 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-9 of 9 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 51 references

Similar Papers

Loading similar papers…